Table I. Effect of gemcitabine on MDSCs and other cells of the immune system.^a.

	Vehicle + PBS	Vehicle + Gemcitabine	α-GalCer + PBS	α-GalCer + Gemcitabine
LN CD11b+Gr1+cells	1.175 ± 0.125	0.11 ± 0.013*	2.02 ± 0.076	0.13 ± 0.027*
spleen CD11b+Gr1+ cells	22.13 ± 0.436	2.61 ± 0.28*	27.73 ± 1.325	1.63 ± 0.275*
LN NK cells	1.32 ± 0.254	1.19 ± 0.245	0.83 ± 0.083	0.83 ± 0.04
spleen NK cells	2.96 ± 0.226	2.88 ± 0.361	2.49 ± 0.226	2.3 ± 0.086
LN B cells	53.85 ± 2.00	54.32 ± 3.29	53.9 ± 2.565	54.1 ± 3.57
spleen B cells	39.12 ± 0.961	40.27 ± 5.577	38.6 ± 4.12	33.85 ± 3.09
LN CD4+ T cells	18.95 ± 2.26	20.65 ± 2.364	19.82 ± 1.024	17.67 ± 0.757
spleen CD4+ T cells	15.32 ± 2.01	15.8 ± 1.277	15.92 ± 0.370	13.52 ± 1.084
LN CD11b−Gr1+ cells	7.7 ± 0.779	5.66 ± 0.581	6.42 ± 0.742	6.54 ± 0.374
spleen CD11b−Gr1+ cells	3.602 ± 0.103	3.167 ± 0.231	3.057 ± 0.381	3.45 ± 0.122

^aEAE was induced in B6 mice and these animals were treated with vehicle or α-GalCer. Mice were also treated at days 6 and 9 after EAE induction with PBS or gemcitabine at 20 mg/kg body weight by i.p. injection. At day 12, mice were sacrificed and the splenic and LN cells were stained with antibodies against MDSCs, NK cells, B cells, CD4⁺ T cells and neutrophils. The data presented are the mean ± SEM percentage of cells from 6 mice and are representative of 3 independent experiments.

^*p<0.05, compared with PBS treatment.